![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A novel combination regimen of peginterferon alfa-2a (40KD) and entecavir results in sustained post-treatment HBsAg clearance in HBeAg-positive chronic hepatitis B
|
|
|
Reported by Jules Levin
AASLD
Nov 5-8 2011 SF
Q. Xie,1 X.F. Bai,2 S.H. Wu,3 J.J. Chen,4 J.F. Sheng,5 Y. Xie,6 C.W. Chen,7 M. Jiang8
1Shanghai Jiaotong University-affiliated Ruijin Hospital, Shanghai, China; 2Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shanxi Province, China; 3the First Affiliated Hospital of Zhengzhou University, Henan, China;4Shanghai Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, Shanghai, China; 5The First Hospital, Zhejiang University, Hangzhou, Zhejiang, China; 6Beijing DiTan Hospital, Beijing, China; 7People's Liberation Army 85 Hospital, Shanghai, China; 8formerly of Roche Pharmaceuticals Co. Ltd., Shanghai, China
![AASLD1.gif](../images/111711/111711-22/AASLD1.gif)
![AASLD2.gif](../images/111711/111711-22/AASLD2.gif)
![AASLD3.gif](../images/111711/111711-22/AASLD3.gif)
![AASLD4.gif](../images/111711/111711-22/AASLD4.gif)
![AASLD5.gif](../images/111711/111711-22/AASLD5.gif)
![AASLD6.gif](../images/111711/111711-22/AASLD6.gif)
![AASLD7.gif](../images/111711/111711-22/AASLD7.gif)
![AASLD8.gif](../images/111711/111711-22/AASLD8.gif)
![AASLD9.gif](../images/111711/111711-22/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|